Theralase Releases Q122 Interim Financial Statements
apnews.com
news
2022-05-30 21:58:06

Press release content from Globe Newswire. The AP news staff was not involved in its creation.TORONTO, May 30, 2022 (GLOBE NEWSWIRE) -- TheralaseÂ® Technologies Inc. ('Theralase' or the 'Company') (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated PhotoDynamic Compounds ('PDC') and their associated drug formulations intended to safely and effectively destroy various cancers has released the Company's unaudited 1Q2022 condensed interim consolidated Financial Statements ('Financial Statements').
